secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-059756
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics Q3 2023 net loss $24.5M; cash $214.7M funds into 2025
------------------------------------------------------------------------

- Net loss of $24.5M ($0.55 per share) vs $26.1M ($0.66) in Q3 2022.
- Revenue of $3.3M from Acadia license/services; cash runway to end of 2025.
- STK-001 Phase 1/2a results plus OLE data expected Q1 2024; then regulatory meeting for Phase 3 design.
- STK-002 Phase 1 study (OSPREY) for ADOA to start in UK early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000095017023059756/0000950170-23-059756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000095017023059756/stok-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-059756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer